Switching from rosiglitazone: Thinking outside the class

JAMA

Volumn 305, Issue 8, 2011, Pages 820-821

  Lipska, Kasia J ^a   Ross, Joseph S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; INCRETIN; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE MARKER; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERVOLEMIA; HYPOGLYCEMIA; LEG EDEMA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OSTEOLYSIS; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 79951983577     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.193     Document Type: Note

References (10)

1. Wilson D. Actos ads jump on Avandia's setback. July 16, 2010. http://prescriptions.blogs.nytimes.com/2010/07/16/actos-ads-jump-on-avandia- woes/. Accessed October 13, 2010.
2. US Food and Drug Administration. Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. December 2008. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed December 15, 2010.
3. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
4. Bolen S, Feldman L, Vassy J, et al. Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386-399. (Pubitemid 351664540)
5. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
6. McEvoy B. Pioglitazone and rosiglitazone cardiovascular safety meta-analysis. Presented at: Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; July 13-14, 2010; Gaithersburg, MD. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739.pdf. Accessed January 23, 2011.
7. Erdmann E, Spanheimer R, Charbonnel B; Proactive Study Investigators. Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the Proactive Study (Proactive 20). J Diabetes. 2010;2(3):212-220.
8. Erdmann E, Charbonnel B, Wilcox RG, et al; Proactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the Proactive Study (Proactive 08). Diabetes Care. 2007;30(11):2773-2778. (Pubitemid 350083116)
9. Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the US, 2003-2009. Diabetes Care. 2010;33(4):823-825.
10. Alexander GC, Sehgal NL,Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168(19):2088-2094.